alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 23.1





Consent of Independent Registered Public Accounting Firm





We consent to the incorporation by reference in the following Registration Statements:





(1) Registration Statement (Form S-3 No. 333-86105, Form S-3 No. 333-35206, Form S-3 No. 333-72614, Form S-3 No. 333-82596, Form S-3 No. 333-101666, Form S-3 No. 333-107836, Form S-3 No. 333-111360, Form S-3 No. 333-118595, Form S-3 No. 333-121297, Form S-3 No. 333-122887, Form S-3 No. 333-128929, Form S-3 No. 333-133786, Form S-3 No. 333-139173, Form S-3 No. 333-151536, Form S-3 No. 333-151654, and Form S-3 No. 333-156237) of Discovery Laboratories, Inc. and in related Prospectuses





(2) Registration Statement (Form S-8 No. 333-148028) pertaining to the Discovery Laboratories, Inc. 2007 Long-Term Incentive Plan





(3) Registration Statement (Form S-8 No. 333-33900, Form S-8 No. 333-55900, Form S-8 No. 333-67422. Form S-8 No. 333-100824,  Form S-8 No. 333-109274, Form S-8 No. 333-116268, Form S-8 No. 333-127790, and Form S-8 No. 333-138476) pertaining to the Amended and Restated 1998 Stock Incentive Plan of Discovery Laboratories, Inc.





(4) Registration Statement (Form S-8 No. 333-59945) pertaining to the Amended and Restated 1998 Stock Incentive Plan of Discovery Laboratories, Inc., the 1996 Stock Option/Stock Issuance Plan of Discovery Laboratories, Inc., and the 1996 Stock Option/ Stock Issuance Plan of Acute Therapeutics, Inc.





(5) Registration Statement (Form S-8 No. 333-37975) pertaining to the Restated 1993 Stock Option Plan of Ansan Pharmaceuticals, Inc. and the 1995 Stock Option Plan of Ansan Pharmaceuticals, Inc.





(6) Registration Statement (Form S-8 No. 333-110412, Form S-8 No. 333-137643, Form S-8 No. 333-156443, Form S-8 No. 333-164470, Form S-8 No. 333-165809, and Form S-8 No. 333-169662) pertaining to the 401(k) Plan of Discovery Laboratories, Inc.





of our report dated March 31, 2011, with respect to the consolidated financial statements of Discovery Laboratories, Inc. and subsidiary, included in this Annual Report (Form 10-K) of Discovery Laboratories, Inc. and subsidiary for the year ended December 31, 2010.





/s/ Ernst & Young LLP





Philadelphia, Pennsylvania


March 31, 2011
# C_2015026EN.01004602.xml

| 26.1.2015 | EN | Official Journal of the European Union | C 26/46 |
| --- | --- | --- | --- |

26.1.2015

EN

Official Journal of the European Union

C 26/46

---

Action brought on 15 October 2014 — ZZ v Commission

(Case F-110/14)

(2015/C 026/61)

Language of the case: French

Parties

Parties

Applicant: ZZ (represented by: S. Orlandi, lawyer)

Applicant:

Defendant: European Commission

Defendant:

Subject-matter and description of the proceedings

Subject-matter and description of the proceedings

The annulment of the decision to credit the applicant’s pension in the European Union’s pension scheme pursuant to the new GIPs relating to Articles 11 and 12 of Annex VIII to the Staff Regulations.

Form of order sought

Form of order sought

| — | Declare that Article 9 of the general implementing provisions of Article 11(2) of Annex VIII is unlawful and, therefore, inapplicable, |
| --- | --- |

—

Declare that Article 9 of the general implementing provisions of Article 11(2) of Annex VIII is unlawful and, therefore, inapplicable,

| — | annul the decision of 24 May 2013 to credit the pension rights acquired by the applicant before his entry into service, in the context of the transfer of those rights into the pension scheme of the institutions of the European Union, pursuant to general implementing provisions of Article 11(2) of Annex VIII to the Staff Regulations of 3 March 2011, |
| --- | --- |

—

annul the decision of 24 May 2013 to credit the pension rights acquired by the applicant before his entry into service, in the context of the transfer of those rights into the pension scheme of the institutions of the European Union, pursuant to general implementing provisions of Article 11(2) of Annex VIII to the Staff Regulations of 3 March 2011,

| — | order the European Commission to pay the costs. |
| --- | --- |

—

order the European Commission to pay the costs.

---
§ 582.5475 Methionine. ( a ) *Product.* Methionine.
( b ) [Reserved]
( c ) *Limitations, restrictions, or explanation.* This substance is generally recognized as safe when used in animal feeds in accordance with good manufacturing or feeding practice.
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
This  Schedule  contains  summary  financial   information  extracted  from  the
financial  statements contained in the body of the accompanying Form 10-K and is
qualified in its entirety by reference to such financial statements.
</LEGEND>
<MULTIPLIER>                                         1

<S>                                                  <C>
<PERIOD-TYPE>  Year
<FISCAL-YEAR-END>                                    Jun-30-1999
<PERIOD-END>   Jun-30-1999
<CASH>                                               0
<SECURITIES>                                         0
<RECEIVABLES>                                        31,678
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                       558,393
<CURRENT-LIABILITIES>                                0
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             1,000
<OTHER-SE>                                           33,807
<TOTAL-LIABILITY-AND-EQUITY>                         558,393
<SALES>                                              0
<TOTAL-REVENUES>                                     3,647
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                     9,875
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                      (6,228)
<INCOME-TAX>                                         (2,711)
<INCOME-CONTINUING>                                  (3,517)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                         (3,517)
<EPS-BASIC>                                        0
<EPS-DILUTED>                                        0


</TABLE>
---

EXHIBIT 13.B





CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In connection with Annual Report of Petaquilla Minerals Ltd. (the Company) on Form 20-F for the fiscal period ended May 31, 2009, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Bassam Moubarak, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:



| |    |  |                                                                                                                                                      
| | -- |  | -----------------------------------------------------------------------------------------------------------------------------------------------------
| | 1. |  | The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and    
| |    |  |                                                                                                                                                      
| | 2. |  | The information contained in the Report fairly presents, in all materials respects, the financial condition and results of operations of the Company.





|                              | 
|----------------------------- | 
|/s/ Bassam Moubarak           | 
|Bassam Moubarak              
|(principal financial officer)



Dated:  September 4, 2009





The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.



---
§ 74.1340 FD&C Red No. 40. ( a ) *Identity and specifications.* ( 1 ) The color additive FD&C Red No. 40 shall conform in identity and specifications to the requirements of § 74.340(a)(1) and (b).
( 2 ) Color additive mixtures for drug use made with FD&C Red No. 40 may contain only those diluents that are suitable and that are listed in part 73 of this chapter as safe for use in color additive mixtures for coloring drugs.
( 3 ) The listing of this color additive includes lakes prepared as described in §§ 82.51 and 82.1051 of this chapter, except that the color additive used is FD&C Red No. 40 and the resultant lakes meet the specification and labeling requirements prescribed by §§ 82.51 or 82.1051 of this chapter.)
( b ) *Uses and restrictions.* ( 1 ) FD&C Red No. 40 and FD&C Red No. 40 Aluminum Lake may be safely used in coloring drugs, including those intended for use in the area of the eye, subject to the restrictions on the use of color additives in § 70.5(b) and (c) of this chapter, in amounts consistent with current good manufacturing practice.
( 2 ) Other lakes of FD&C Red No. 40 may be safely used in coloring drugs, subject to the restrictions on the use of color additives in § 70.5 of this chapter, in amounts consistent with current good manufacturing practice.
( c ) *Labeling.* The label of the color additive and any lakes or mixtures prepared therefrom intended solely or in part for coloring purposes shall conform to the requirements of § 70.25 of this chapter.
( d ) *Certification.* All batches of FD&C Red No. 40 and lakes thereof shall be certified in accordance with regulations, in part 80 of this chapter.
[42 FR 15654, Mar. 22, 1977, as amended at 59 FR 7636, Feb. 16, 1994]
§ 520.1450c Morantel tartrate sustained-release trilaminate cylinder/sheet. ( a ) *Specifications.* The drug product consists of a trilaminated, perforated, plastic sheet formed into a cylinder having plastic plugs in its ends. The core lamina contains 19.8 grams of morantel tartrate equivalent to 11.8 grams of morantel base.
( b ) *Sponsor.* See 054771 in § 510.600(c) of this chapter.
( c ) *Related tolerances.* See § 556.425 of this chapter.
( d ) *Conditions of use* — ( 1 ) *Amount.* Grazing cattle: Administer 1 cartridge to each animal at the start of the grazing season.
( 2 ) *Indications for use.* For control of the adult stage of the following gastrointestinal nematode infections in weaned calves and yearling cattle weighing a minimum of 200 pounds: *Ostertagia* spp., *Trichostrongylus axei, Cooperia* spp., and *Oesophagostomum radiatum.*
( 3 ) *Limitations.* Administer orally with the dosing gun to all cattle that will be grazing the same pasture. Effectiveness of the drug product is dependent upon continuous control of the gastrointestinal parasites for approximately 90 days following administration. Therefore, treated cattle should not be moved to pastures grazed in the same grazing season/calendar year by untreated cattle. Do not administer to cattle within 102 days of slaughter. Consult your veterinarian before administering to severely debilitated animals and for assistance in the diagnosis, treatment, and control of parasitism.
[56 FR 13396, Apr. 2, 1991, as amended at 78 FR 28825, May 20, 2014]
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE BALANCE
SHEETS AND STATEMENTS OF OPERATIONS FOUND ON THE FORM 10-QSB FOR THE SIX MONTH
PERIOD ENDED JUNE 30, 1999 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH
CONSOLIDATED FINANCIAL STATEMENTS.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               JUN-30-1999
<CASH>                                         192,973
<SECURITIES>                                         0
<RECEIVABLES>                                1,132,351
<ALLOWANCES>                                  (54,179)
<INVENTORY>                                  2,137,103
<CURRENT-ASSETS>                             3,599,682
<PP&E>                                       2,437,737
<DEPRECIATION>                               1,104,329
<TOTAL-ASSETS>                               5,780,283
<CURRENT-LIABILITIES>                        3,077,746
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        17,489
<OTHER-SE>                                   2,038,349
<TOTAL-LIABILITY-AND-EQUITY>                 5,780,283
<SALES>                                      4,322,441
<TOTAL-REVENUES>                             4,322,441
<CGS>                                        3,041,231
<TOTAL-COSTS>                                1,418,065
<OTHER-EXPENSES>                                36,021
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             105,615
<INCOME-PRETAX>                              (278,491)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                          (278,491)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (278,491)
<EPS-BASIC>                                     (.016)
<EPS-DILUTED>                                   (.016)


</TABLE>
I 

118TH CONGRESS 

1ST SESSION H. R. 776 

To amend section 524(c) of title 18, United States Code, to use lawfully 

forfeited drug seizures to increase border security. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 2, 2023 

Mr. DUNCAN (for himself, Mrs. HARSHBARGER, Mr. NORMAN, Mrs. MILLER

of Illinois, Mr. GOSAR, Mr. MOONEY, Mr. MOORE of Alabama, Mr. 

POSEY, Mr. ZINKE, and Mr. CARTER of Georgia) introduced the following 

bill; which was referred to the Committee on the Judiciary 

A BILL 

To amend section 524(c) of title 18, United States Code, 

to use lawfully forfeited drug seizures to increase border 

security. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Build up Illegal Line 

5 Defenses with Assets Lawfully Lifted Act of 2023’’. 


pbinns on DSKJLVW7X2PROD with $$_JOB
2 

•HR 776 IH

1 SEC. 2. RESERVATION OF PORTION OF FORFEITS IN THE 

2 DEPARTMENT OF JUSTICE CIVIL ASSET FOR3 FEITURE FUND FOR BUILDING A PHYSICAL 

4 BARRIER OR ADVANCED TECHNOLOGY TO 

5 PREVENT ILLEGAL ENTRY OVER OUR SOUTH6 ERN BORDER. 

7 Section 524(c) of title 28, United States Code, is 

8 amended— 

9 (1) in paragraph (1), by inserting ‘‘, except as 

10 provided in paragraph (12),’’ before ‘‘be available to 

11 the Attorney General’’; and 

12 (2) by adding at the end the following: 

13 ‘‘(12)(A) Not later than on December 1 of each 

14 year, the Attorney General shall report to Congress 

15 the total of any funds in the Fund as of October 1 

16 which are derived from Mexican cartels. 

17 ‘‘(B) The Attorney General shall conduct an on18 going study with a view to deriving more funds than 

19 have historically been the case for the Fund from 

20 Mexican cartels. The Attorney General shall report 

21 from time to time to Congress any suggestions found 

22 through the study. The first such report shall be 

23 transmitted not later than 180 days after the date 

24 of the enactment of this paragraph. 

25 ‘‘(C) An amount equal to 50 percent of the 

26 total reported under subsection (a) shall be made 


pbinns on DSKJLVW7X2PROD with $$_JOB
3 

•HR 776 IH

1 available without fiscal year limitation to install ad2 ditional physical barriers and roads (including the 

3 removal of obstacles to detection of illegal entrants) 

4 in the vicinity of the United States border to deter 

5 illegal crossings in areas of high illegal entry into 

6 the United States.’’. 

7 SEC. 3. LIMITATION ON RELEASE OF PROPERTY. 

8 Section 983(f)(8) of title 18, United States Code, is 

9 amended— 

10 (1) by striking ‘‘or’’ at the end of subparagraph 

11 (C); 

12 (2) by striking the period at the end of sub13 paragraph (D) and inserting ‘‘; or’’; and 

14 (3) by adding at the end the following: 

15 ‘‘(E) is currency or contraband likely to 

16 belong to or used in support of a foreign, illegal 

17 trafficking organization.’’. 

Æ 


pbinns on DSKJLVW7X2PROD with $$_JOB
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM UNAUDITED
CONDENSED CONSOLIDATED FINANCIAL STATEMENT AS OF THE QUARTER ENDED MARCH 29,
1998 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FORM 10Q FOR THE
QUARTER ENDED MARCH 29, 1998
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-27-1998
<PERIOD-START>                             DEC-29-1997
<PERIOD-END>                               MAR-29-1998
<CASH>                                          33,861
<SECURITIES>                                         0
<RECEIVABLES>                                    4,145
<ALLOWANCES>                                         0
<INVENTORY>                                      4,308
<CURRENT-ASSETS>                                45,865
<PP&E>                                         258,110
<DEPRECIATION>                                  76,848
<TOTAL-ASSETS>                                 287,566
<CURRENT-LIABILITIES>                          104,914
<BONDS>                                        212,596
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                            10
<OTHER-SE>                                    (34,414)
<TOTAL-LIABILITY-AND-EQUITY>                   287,566
<SALES>                                        113,306
<TOTAL-REVENUES>                               113,306
<CGS>                                           30,763
<TOTAL-COSTS>                                  115,562
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               5,827
<INCOME-PRETAX>                                (8,083)
<INCOME-TAX>                                       127
<INCOME-CONTINUING>                            (8,210)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (8,210)
<EPS-PRIMARY>                                        0
<EPS-DILUTED>                                        0
        

</TABLE>
# C_2019082EN.01002501.xml

| 4.3.2019 | EN | Official Journal of the European Union | C 82/25 |
| --- | --- | --- | --- |

4.3.2019

EN

Official Journal of the European Union

C 82/25

---

Judgment of the General Court of 12 December 2018 — Teva UK and Others v Commission

(Case T-679/14) (1)

((Competition - Agreements, decisions and concerted practices - Perindopril market, medicinal product intended for the treatment of cardiovascular diseases, in its originator and generic versions - Decision finding an infringement of Article 101 TFEU - Principle of impartiality - Consultation of the Advisory Committee on Restrictive Practices and Dominant Positions - Patent dispute settlement and exclusive purchasing agreement - Potential competition - Restriction of competition by object - Balance between competition law and patent law - Conditions for exemption under Article 101(3) TFEU - Fines))

(2019/C 82/27)

Language of the case: English

Parties

Applicants: Teva UK Ltd (West Yorkshire, United Kingdom), Teva Pharmaceuticals Europe BV (Utrecht, Netherlands), Teva Pharmaceutical Industries Ltd (Jerusalem, Israel) (represented by D Tayar and A. Richard, lawyers)

Defendant: European Commission (represented initially by F. Castilla Contreras, T. Vecchi and B. Mongin, and subsequently by F. Castilla Contreras, B. Mongin and C. Vollrath, acting as Agents, and by G. Peretz, Barrister)

Intervener in support of the applicants: European Generic medicines Association AISBL (EGA) (Brussels, Belgium) (represented by S.-P. Brankin, Solicitor, and E. Wijckmans, lawyer)

Re:

Application under Article 263 TFEU for annulment of Commission Decision C(2014) 4955 final of 9 July 2014 relating to a proceeding under Article 101 and Article 102 TFEU [Case AT.39612 — Perindopril (Servier)] in so far as it concerns the applicants and, in the alternative, for reduction of the fine imposed on the applicants by that decision.

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders Teva UK Ltd, Teva Pharmaceuticals Europe BV and Teva Pharmaceutical Industries Ltd to pay, in addition to their own costs, the costs incurred by the Commission; |
| --- | --- |

2.

Orders Teva UK Ltd, Teva Pharmaceuticals Europe BV and Teva Pharmaceutical Industries Ltd to pay, in addition to their own costs, the costs incurred by the Commission;

| 3. | Orders the European Generic medicines Association AISBL (EGA) to bear its own costs. |
| --- | --- |

3.

Orders the European Generic medicines Association AISBL (EGA) to bear its own costs.

---

(1)  OJ C 409, 17.11.2014.

---